Astrazeneca Pharma India rose 2.34% to Rs 2202 after the company received import and market permission in Form 45 from Drugs Controller General of India for anti-diabetic medication.
AstraZeneca Pharma India announced after market hours yesterday, 25 September 2019, that it received import and market permission in Form 45 (marketing authorization) from the Drugs Controller General of India (DGCA) for fixed dose combination (FDC) of dapagliflozin 10mg + saxagliptin 5mg film coated tablets.The receipt of this import and market permission paves way for the launch of FDC of dapagliflozin 10mg + saxagliptin 5mg film coated tablets (QTERN) in India, subject to the receipt of other related statutory approvals and licenses.
QTERN is a prescription medicine that contains dapagliflozin and saxagliptin. QTERN is used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes.
Meanwhile, the S&P BSE Sensex was up 421 points or 1.09% to 39014.31.
On the BSE, 759 shares were traded in the Astrazeneca Pharma counter so far compared with average daily volumes of 1629 shares in the past one quarter. The stock hit a high of Rs 2216.85 and a low of Rs 2185.1 so far during the day.
The stock hit a 52-week high of Rs 2398.55 on 30 Apr 2019. The stock hit a 52-week low of Rs 1306.8 on 07 Dec 2018.
Astrazen's net profit rose 236.8% to Rs 21.52 crore on a 26.7% increase in net sales to Rs 204.56 crore in Q1 June 2019 over Q1 June 2018.
More From This Section
AstraZeneca Pharma India (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a subsidiary of AstraZeneca Plc, UK. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular and & metabolic diseases, oncology and respiratory.
Powered by Capital Market - Live News